643 related articles for article (PubMed ID: 33564683)
1. Comparison of Immune Response between SARS, MERS, and COVID-19 Infection, Perspective on Vaccine Design and Development.
Ansariniya H; Seifati SM; Zaker E; Zare F
Biomed Res Int; 2021; 2021():8870425. PubMed ID: 33564683
[TBL] [Abstract][Full Text] [Related]
2. Lessons for COVID-19 Immunity from Other Coronavirus Infections.
Sariol A; Perlman S
Immunity; 2020 Aug; 53(2):248-263. PubMed ID: 32717182
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2: previous coronaviruses, immune response, and development of vaccines.
De León-Rodríguez SG; Hernández-Rico B; Olmo-Vázquez GD; Cruz-Dávalos I; Bonifaz LC
Bol Med Hosp Infant Mex; 2020; 77(5):252-261. PubMed ID: 33064679
[TBL] [Abstract][Full Text] [Related]
4. Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development.
Begum J; Mir NA; Dev K; Buyamayum B; Wani MY; Raza M
Transbound Emerg Dis; 2021 May; 68(3):1111-1124. PubMed ID: 32815655
[TBL] [Abstract][Full Text] [Related]
5. A systematic review of SARS-CoV-2 vaccine candidates.
Dong Y; Dai T; Wei Y; Zhang L; Zheng M; Zhou F
Signal Transduct Target Ther; 2020 Oct; 5(1):237. PubMed ID: 33051445
[TBL] [Abstract][Full Text] [Related]
6. Innate Immune Responses to Highly Pathogenic Coronaviruses and Other Significant Respiratory Viral Infections.
Ahmed-Hassan H; Sisson B; Shukla RK; Wijewantha Y; Funderburg NT; Li Z; Hayes D; Demberg T; Liyanage NPM
Front Immunol; 2020; 11():1979. PubMed ID: 32973803
[TBL] [Abstract][Full Text] [Related]
7. Immune Responses to SARS-CoV, MERS-CoV and SARS-CoV-2.
İnandıklıoğlu N; Akkoc T
Adv Exp Med Biol; 2020; 1288():5-12. PubMed ID: 32514817
[TBL] [Abstract][Full Text] [Related]
8. Coronavirus vaccine development: from SARS and MERS to COVID-19.
Li YD; Chi WY; Su JH; Ferrall L; Hung CF; Wu TC
J Biomed Sci; 2020 Dec; 27(1):104. PubMed ID: 33341119
[TBL] [Abstract][Full Text] [Related]
9. Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection.
Liang Y; Wang ML; Chien CS; Yarmishyn AA; Yang YP; Lai WY; Luo YH; Lin YT; Chen YJ; Chang PC; Chiou SH
Front Immunol; 2020; 11():1022. PubMed ID: 32574260
[TBL] [Abstract][Full Text] [Related]
10. Research progress and challenges to coronavirus vaccine development.
Zhou P; Li Z; Xie L; An D; Fan Y; Wang X; Li Y; Liu X; Wu J; Li G; Li Q
J Med Virol; 2021 Feb; 93(2):741-754. PubMed ID: 32936465
[TBL] [Abstract][Full Text] [Related]
11. [Strategies for vaccine development of COVID-19].
Yang L; Tian D; Liu W
Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):593-604. PubMed ID: 32347054
[TBL] [Abstract][Full Text] [Related]
12. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
13. T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV.
Liu WJ; Zhao M; Liu K; Xu K; Wong G; Tan W; Gao GF
Antiviral Res; 2017 Jan; 137():82-92. PubMed ID: 27840203
[TBL] [Abstract][Full Text] [Related]
14. A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2.
Atzrodt CL; Maknojia I; McCarthy RDP; Oldfield TM; Po J; Ta KTL; Stepp HE; Clements TP
FEBS J; 2020 Sep; 287(17):3633-3650. PubMed ID: 32446285
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the potential impact of targeted vaccination strategies against severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) outbreaks in the healthcare setting.
Abdirizak F; Lewis R; Chowell G
Theor Biol Med Model; 2019 Oct; 16(1):16. PubMed ID: 31587665
[TBL] [Abstract][Full Text] [Related]
16. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic.
Prompetchara E; Ketloy C; Palaga T
Asian Pac J Allergy Immunol; 2020 Mar; 38(1):1-9. PubMed ID: 32105090
[TBL] [Abstract][Full Text] [Related]
17. A Comparison of the Clinical, Viral, Pathologic, and Immunologic Features of Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and Coronavirus 2019 (COVID-19) Diseases.
Barth RF; Buja LM; Barth AL; Carpenter DE; Parwani AV
Arch Pathol Lab Med; 2021 Oct; 145(10):1194-1211. PubMed ID: 34232978
[TBL] [Abstract][Full Text] [Related]
18. The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections.
Zhang YY; Li BR; Ning BT
Front Immunol; 2020; 11():2033. PubMed ID: 32922406
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 Causes a Different Cytokine Response Compared to Other Cytokine Storm-Causing Respiratory Viruses in Severely Ill Patients.
Olbei M; Hautefort I; Modos D; Treveil A; Poletti M; Gul L; Shannon-Lowe CD; Korcsmaros T
Front Immunol; 2021; 12():629193. PubMed ID: 33732251
[TBL] [Abstract][Full Text] [Related]
20. The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies.
Molaei S; Dadkhah M; Asghariazar V; Karami C; Safarzadeh E
Int Immunopharmacol; 2021 Mar; 92():107051. PubMed ID: 33429331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
